Please assess the completion status of the following clinical trial:

Trial Title: Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic adult Fabry patients (≥18 yrs)~* Males: plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than lower limit of normal (LLN in plasma=3.2 nmol/hr/ml, LLN in leucocytes=32 nmol/hr/mg/protein)~* Females: historical genetic test results consistent with Fabry mutations~* Globotriaosylceramide (Gb3) concentration in urine \> 1.5 times upper normal limit~* Patients who have never received enzyme replacement therapy (ERT) in the past, or patients who have not received ERT in the past 6 months and have a negative anti alpha galactosidase antibody test~* eGFR ≥ 60 mL/min/1.73m2~* The patient signs informed consent~* Female patients and male patients whose co-partners are of child-bearing potential agree to use a medically acceptable method of contraception, not including the rhythm method~Exclusion Criteria:~* Participation in any trial of an investigational drug within 30 days prior to study screening~* Chronic kidney disease stages 3-5 (CKD 3-5) (Appendix 7)~* History of dialysis or renal transplantation~* Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy initiated or dose changed in the 4 weeks prior to screening~* Severe myocardial fibrosis by MRI (≥2 late-enhancement \[LE\] positive left ventricular segments) (Weidemann et al. 2009)~* History of clinical stroke~* Pregnant or nursing~* Presence of HIV and/or HBsAg and/or Hepatitis C infections~* Known allergies to ERT~* Known allergy to Gadolinium based contrast agents~* Presence of any medical, emotional, behavioral or psychological condition that, in the judgment of the Investigator and/or Medical Director, would interfere with the patient's compliance with the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.2 mg/kg (Type: EXPERIMENTAL): PRX-102 0.2 mg/kg every 2 weeks
- 1 mg/kg (Type: EXPERIMENTAL): PRX-102 1 mg/kg every 2 weeks
- 2 mg/kg (Type: EXPERIMENTAL): PRX-102 2 mg/kg every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).